期刊文献+

地西他滨治疗成人急性髓细胞白血病的临床观察 被引量:32

Clinical observation of decitabine treatment for patients with acute myeloid leukemia
原文传递
导出
摘要 目的:探讨地西他滨治疗成人急性髓细胞白血病(acutemyeloid leukemia,AML)的临床疗效和安全性。方法:收集2009年8月—2010年10月在本科接受地西他滨治疗的15例AML患者(年龄>18岁)的临床资料,评价其疗效和不良反应。结果:15例患者中,完全缓解3例,部分缓解5例,总有效率为53.3%。在12例可行细胞遗传学评价的患者中,1例(8.3%)获得完全细胞遗传学缓解。中位总生存期为123d(27~509d),中位无复发生存期为70d(19~306d),中位反应持续时间为33d(11~176d)。Ⅳ级血液学不良反应发生率为93.3%,Ⅲ~Ⅳ级感染发生率为33.3%,无Ⅲ~Ⅳ级出血、恶心呕吐和肝功能损伤。早期死亡1例。结论:地西他滨可有效治疗成人急性髓细胞白血病,血液学不良反应较重,必须给予积极的支持治疗。 Objective:To evaluate the clinical therapeutic effect and safety of decitabine in the treatment for adult acute myeloid leukemia(AML).Methods:Clinical information from 15 patients(18 years) with adult AML were collected between August 2009 and October 2010.The therapeutic effect and side reactions of decitabine were evaluated.Results:Of the 15 patients,3 patients achieved complete remission(CR),five patients achieved partial remission(PR).The overall response rate was 53.3%.Of the 12 patients whose cytogenetic evaluation was accessible,one patient(8.3%) achieved complete cytogenetic remission.The median overall survival(OS) was 123 d(27-509 d),the median relapse-free survival(RFS) was 70 d(19-306 d),and the median duration of response was 33 d(11-176 d).The incidence rate of grade Ⅳ hematologic toxicity was 93.3%,and the incidence rate of grade Ⅲ-Ⅳ infection was 33.3%.No severe bleeding,nausea and vomiting and liver injury(grade Ⅲ-Ⅳ) were observed.Early death occurred in one patient.Conclusion:Decitabine can effectively treat adult AML with more severe hematologic toxicity,and it is necessary to give active supportive treatment.
出处 《肿瘤》 CAS CSCD 北大核心 2011年第11期1022-1025,共4页 Tumor
基金 国家科技支撑计划资助项目(编号:2008BAI61B02) 国家科技重大专项课题资助项目(编号:2008ZX09312-026) 江苏省高校自然科学研究面上项目(编号:09KJB320015) 江苏高校优势学科建设工程资助项目
关键词 白血病 髓样 地西他滨 不良反应 Leukemia myeloid Decitabine Adverse reaction
  • 相关文献

参考文献12

  • 1CHESON B D,BENNETT J M,KOPECKY K J,et al.Revised recommendations of the International Working Group for Diagnosis,Standardization of Response Criteria,Treatment Outcomes,and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia[J].J Clin Oncol,2003,21(24):4642-4649.
  • 2STRESEMANN C,BRUECKNER B,MUSCH T,et al.Functional diversity of DNA methyltransferase inhibitors in human cancer cell lins[J].Cancer Res,2006,66 (5):2794-2800.
  • 3WlDSCHWENDTER A,M(U)LLER H M,FIEGL H,et al.DNA methylation in serum and tumors of cervical cancer patients[J].Clin Cancer Res,2004,10 (2):565-571.
  • 4MURAl M,TOYOTA M,SATOH A,et al.Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours[J].Br J Cancer,2005,92 (6):1165-1172.
  • 5HASEGAWA D,MANABE A,KUBOTA T,et al.Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia[J].Br J Haematol,2005,128 (6):805-81 2.
  • 6JIANG Y,DUNBAR A,GONDEK L P,et al.Aberrant DNA methylation is a dominant mechanism in MDS progression to AML[J].Blood,2009,113 (6):1315-1325.
  • 7Sl J,BOUMBER Y A,SHU J,et al.Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation[J].Cancer Res,2010,70 (17):6968-6977.
  • 8ISSA J P,GARCIA-MANERO G,GILES F J,et al.Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza2'-deoxycytidine (decitabine) in hematopoietic malignancies[J].Blood,2004,103 (5):1635-1640.
  • 9BLUM W,KLISOVIC R B,HACKANSON B,et al.Phase Ⅰ study of decitabine alone or in combination with valproic acid in acute myeloid leukemia[J].J Clin Oncol,2007,25 (25):3884-3891.
  • 10GARCIA-MANERO G,KANTARJIAN H M,SANCHEZGONZALEZ B,et al.Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia[J].Blood,2006,108 (10):3271-3279.

同被引文献286

引证文献32

二级引证文献226

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部